BREAST cancer sufferers in Wales hailed the rollout of a new drug today, which can extend the life of incurable patients.

The drug Capivasertib has been proven to extend the life of some people with incurable breast cancer and is now available to Welsh NHS patients.

There are more than 2,000 people in Wales diagnosed with breast cancer every year.

Breast cancer is the most common cancer in Britain, with one in seven women affected in their lifetimes and 75 per cent surviving for 10 years or more after diagnosis.

Capivasertib works for patients with certain gene mutations that affect up to half of people with hormone receptor-positive secondary breast cancer.

Although hormone therapy usually works, eventually the cancer can become resistant.

Cancer specialists said patients receiving Capivasertib had an extra 39 months, a doubling of the survival time, and hailed a real-life impact for people to spend extra time with their relatives and friends.